Literature DB >> 22068047

Thymidine kinase and cancer monitoring.

Stefan Aufderklamm1, Tilman Todenhöfer, Georgios Gakis, Stephan Kruck, Joerg Hennenlotter, Arnulf Stenzl, Christian Schwentner.   

Abstract

Thymidine kinases (TK) have a key function in the synthesis of DNA. Two isoenzymes have been characterized: TK1 is cell cycle-dependent and present in the cytoplasm whereas TK2--located in mitochondria--is cell cycle-independent. The diagnostic and prognostic role of TK1 has recently been investigated. TK1 might be helpful for screening and monitoring of human malignancies. TK1 may also serve as a prognostic factor for progression. Herein, we summarize the status of TK1 for cancer monitoring and point out its use as a proliferation marker. A comprehensive overview about the association of TK-1 with various entities is given.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22068047     DOI: 10.1016/j.canlet.2011.10.025

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  24 in total

1.  Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial.

Authors:  Lucia Zanoni; Alessandro Broccoli; Alessandro Lambertini; Cinzia Pellegrini; Vittorio Stefoni; Filippo Lodi; Cristina Fonti; Cristina Nanni; Pier Luigi Zinzani; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-17       Impact factor: 9.236

2.  Serum thymidine kinase 1 is a reliable maker for the assessment of the risk of developing malignancy: A case report.

Authors:  Zhiheng Chen; Hong Guan; Hong Yuan; Xia Cao; Yingxin Liu; J I Zhou; Ellen He; Sven Skog
Journal:  Oncol Lett       Date:  2015-06-30       Impact factor: 2.967

Review 3.  A review of HPRT and its emerging role in cancer.

Authors:  Michelle H Townsend; Richard A Robison; Kim L O'Neill
Journal:  Med Oncol       Date:  2018-05-05       Impact factor: 3.064

4.  Thymidine kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis.

Authors:  Xiaole Zhu; Chenyuan Shi; Yunpeng Peng; Lingdi Yin; Min Tu; Qiuyang Chen; Chaoqun Hou; Qiang Li; Yi Miao
Journal:  Cell Prolif       Date:  2017-12-20       Impact factor: 6.831

Review 5.  The proliferation marker thymidine kinase 1 in clinical use.

Authors:  Ji Zhou; Ellen He; Sven Skog
Journal:  Mol Clin Oncol       Date:  2012-09-04

6.  Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis.

Authors:  Yanqun Xiang; Hua Zeng; Xiang Liu; Hui Zhou; Ling Luo; Chaohui Duan; Xiaohong Luo; Haiyan Yan
Journal:  Biomed Rep       Date:  2013-05-28

7.  Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.

Authors:  Kazuki Sakamoto; Tatsushi Yokogawa; Hiroyuki Ueno; Kei Oguchi; Hiromi Kazuno; Keiji Ishida; Nozomu Tanaka; Akiko Osada; Yukari Yamada; Hiroyuki Okabe; Kenichi Matsuo
Journal:  Int J Oncol       Date:  2015-04-20       Impact factor: 5.650

Review 8.  Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review.

Authors:  Sonja Schelhaas; Kathrin Heinzmann; Vikram R Bollineni; Gerbrand M Kramer; Yan Liu; John C Waterton; Eric O Aboagye; Anthony F Shields; Dmitry Soloviev; Andreas H Jacobs
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

9.  Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix.

Authors:  Gang Chen; Cheng He; Ling Li; An Lin; Xiongwei Zheng; Ellen He; Sven Skog
Journal:  BMC Cancer       Date:  2013-05-21       Impact factor: 4.430

10.  Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.

Authors:  Imanol Arozarena; Ibai Goicoechea; Oihane Erice; Jennnifer Ferguson; Geoffrey P Margison; Claudia Wellbrock
Journal:  Mol Cancer       Date:  2014-06-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.